Thursday, September 28, 2023 3pm to 4pm
About this Event
Understand cellular and gene therapy risks, benefits and opportunities.
Understand the unique ethical challenges to gene replacement therapy clinical trials, specifically in rare and ultrarare disease populations.
Discuss ethical considerations regarding enrolling vulnerable populations, including critically ill patients and their families on investigational clinical studies.
As a condition for receiving federal funding for health research training grants and career development awards, federal funders (including NIH, DOD, and NSF) mandates all participants in training grants to receive training in RCR.
Visit ctsicn.org/RCR to learn more about RCR Training Requirements.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of INOVA and Children’s National Hospital. The INOVA Office of Continuing Medical Education is accredited by the MSV to provide continuing medical education for physicians.
Children's National Hospital is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
The Inova Office of Continuing Medical Education designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physicians may claim up to 1.0 credit in Type 1 CME on the Virginia Board of Medicine Continued Competency and Assessment Form required for renewal of an active medical license in Virginia.
Where:Online
1 person is interested in this event
User Activity
No recent activity